Please assess the completion status of the following clinical trial:

Trial Title: Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Patients must:~* Have relapsing remitting multiple sclerosis~* Have been on treatment with natalizumab for at least 6 months prior to screening and discontinuation is an option.~Exclusion Criteria:~Patients with:~* History of chronic immune disease~* Crohn's disease~* Certain cancers~* Uncontrolled diabetes~* Certain eye disorders~* Negative for varicella-zoster virus IgG antibodies~* Certain hepatic conditions~* Low white blood cell count~* On certain immunosuppressive medications or heart medications~* Resting heart rate less than 45 bpm.~* Certain heart conditions or certain lung conditions~* Inability to undergo MRI scans~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 8-week washout + Fingolimod (FTY720) (Type: EXPERIMENTAL): 8-week washout (8 weeks no treatment) followed by 24 weeks of treatment with fingolimod 0.5mg once a day
- 12-week washout + Fingolimod (FTY720) (Type: EXPERIMENTAL): 12-week washout (8 weeks no treatment and 4 weeks placebo) followed by 20 weeks of treatment with fingolimod 0.5mg once a day
- 16-week washout + Fingolimod (FTY720) (Type: EXPERIMENTAL): 16-week washout (8 weeks no treatment and 8 weeks placebo) followed by 16 weeks of treatment with fingolimod 0.5mg once a day

Based on this trial design, predict the completion outcome and termination type (if applicable).